ホーム › 非小細胞肺癌 › テキサス › Fort Worth
Fort Worth、TXにおける非小細胞肺癌の臨床試験
Fort Worthとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- START Center for Clinical Research, Fort Worth
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
被験者募集中第3相
- The Center For Cancer And Blood Disorders, Fort Worth
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
被験者募集中第2相
- START Fort Worth, Fort Worth
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Texas Oncology - DFW, Fort Worth
- The Center for Cancer and Blood Disorders, Fort Worth
- The Center for Cancer and Blood Disorders, Burleson · 13マイル先
- 他1件
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Texas Oncology - DFW, Fort Worth
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- The Center for Cancer and Blood Disorders, Fort Worth
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Fort Worth
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, Fort Worth
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Fort Worth
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
被験者募集中第1/2相
- Start Dfw, Fort Worth
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- JPS Health Network, Fort Worth
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
被験者募集中第1相
- Texas Oncology - DFW, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- USOR Texas Oncology, Fort Worth
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
被験者募集中第1相
- UT Southwestern - Simmons Cancer Center - Fort Worth, Fort Worth
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
被験者募集中第2相
- Start Ccbd, Llc, Fort Worth
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
被験者募集中第1相
- START Dallas Fort Worth, LLC, Fort Worth
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
被験者募集中第1相
- START Dallas Fort Worth, LLC, Fort Worth
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
被験者募集中第1相
- START Dallas, Fort Worth
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Fort Worthにおける他の研究
- 卵巣がん17件の研究
- 子宮内膜がん12件の研究
- 乳がん12件の研究
- がん（全種類）9件の研究
- 前立腺がん9件の研究
- トリプルネガティブ乳がん7件の研究
- 黄斑変性症7件の研究
- 潰瘍性大腸炎7件の研究
- 腎臓がん（腎細胞がん）7件の研究
- 心不全7件の研究
- 転移性癌7件の研究
- 大腸癌7件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。